Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.
The aim of this study: to determine which patients need biologic therapy after starting methotrexate.
Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.
The choice of a biologic agent for treating rheumatoid arthritis (RA) may influence a patient’s risk of serious infections.